KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Arbutus Biopharma (ABUS) over the last 15 years, with Q3 2025 value amounting to $9.2 million.

  • Arbutus Biopharma's Total Non-Current Liabilities fell 6347.16% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 6347.16%. This contributed to the annual value of $24.1 million for FY2024, which is 2165.81% down from last year.
  • Latest data reveals that Arbutus Biopharma reported Total Non-Current Liabilities of $9.2 million as of Q3 2025, which was down 6347.16% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Total Non-Current Liabilities ranged from a high of $55.6 million in Q1 2022 and a low of $9.2 million during Q3 2025
  • Over the past 5 years, Arbutus Biopharma's median Total Non-Current Liabilities value was $27.9 million (recorded in 2024), while the average stood at $28.9 million.
  • As far as peak fluctuations go, Arbutus Biopharma's Total Non-Current Liabilities skyrocketed by 33688.02% in 2022, and later crashed by 6792.39% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Total Non-Current Liabilities (Quarter) stood at $18.8 million in 2021, then skyrocketed by 157.08% to $48.2 million in 2022, then crashed by 36.14% to $30.8 million in 2023, then decreased by 21.66% to $24.1 million in 2024, then plummeted by 61.81% to $9.2 million in 2025.
  • Its last three reported values are $9.2 million in Q3 2025, $9.5 million for Q2 2025, and $27.3 million during Q1 2025.